Optimizing Therapy in HER2+ Disease with Dr. Hope S. Rugo

HER2+ early breast cancer has been revolutionized by the development of HER2 directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. This program is designed to review and discuss the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity, review the addition of pertuzumab to a trastuzumab-based adjuvant regimen and discuss improvement of pathologic complete response rates and invasive disease-free survival, and review the addition of neratinib for patients with high-risk disease and discuss improvement disease-in free survival.

Get Started Now

Enroll in Course

Learning Objectives

Review and discuss the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity.

Review the addition of pertuzumab to a trastuzumab-based adjuvant regimen and discuss improvement of pathologic complete response rates and invasive disease-free survival.

Review the addition of neratinib for patients with high-risk disease and discuss improvement disease-in free survival.

Accreditation Information

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
Amedco LLC designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Amedco LLC designates this activity for a maximum of .75 ANCC contact hours.

Pharmacists
Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours.

 

How This Course Works

This course is a 45 min video on Optimizing Therapy in HER2+ Disease. 

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

A link to the evaluation will be provided at the conclusion of the course.

If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.

 

Frequently Asked Questions

How do I access my CME/CE Credits?

A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.

How long do I have access to the course?

This CME course will be available to access until August 2023.

Can I have face to face interaction with Instructor?

No, this is an online self-paced course with video demonstration. However, you are free to connect with the medical experts for each session on social media or contact the team and we will connect you. 

How many credits can I obtain?

Amedco LLC designates this enduring activity for a maximum of .75 AMA PRA Category 1 CreditsTM for physicians and .75 contact hours for nurses and .75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.  

Course Curriculum

  • Optimizing Therapy in HER2+ Disease | Dr. Hope S. Rugo Learner Notification
    5 minutes
  • Optimizing Therapy in HER2+ Disease | Hope S. Rugo, MD
    50 minutes

Get Started Now

Enroll in Course